CD95 system counter attack and prognostic impact

Onkologie

Volumn 29, Issue 8-9, 2006, Pages 358-359

  Debatin, Klaus Michael ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; CHEMOTHERAPY; EDITORIAL; HUMAN; IMMUNITY; IN VITRO STUDY; MELANOMA; METASTASIS; PANCREAS ISLET; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIGENS, CD95; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTORS;

EID: 33748532889     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094698     Document Type: Editorial

References (22)

1. Debatin K, Krammer P: Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
2. Green DR, Ferguson TA: The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001;2:917-24.
3. Igney FH, Behrens C, Krammer PH: Tumor counterattack-concept and reality. Eur J Immunol 2000;30:725-31.
4. French LE, Tschopp J: Defective death receptor signaling as a cause of tumor immune escape. Cancer Biol 2002;12:51-55.
5. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-66.
6. Restifo NP: Countering the 'counterattack' hypothesis. Nat Med 2001;7:259.
7. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
8. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-32.
9. Lau HT, Yu M, Fontana M, Stoeckert Jr CJ: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-12.
10. Kang SM, Hoffman A, Le D, Spinger LM, Stock PG, Blau HM: Immune response and myoblasts that express Fas ligand. Science 1997;278:1322-24.
11. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738-43.
12. Allison J, Georgiou HM, Strasser A, Vaux DL: Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997;94:3943-47.
13. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.
14. Hahne M, Rimoldi D, Schroeter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerrottini J, Tschopp J: Melanoma cell expression of Fas (Apo-1/CD95)ligand: implications for tumor immune escape. Science 1996;274:1363-66.
15. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
16. Villunger A, Strasser A: The great escape: is immuneevasion required for tumor progression? Nat Med 1999;5:874-75.
17. Tanaka M, Itai T, Adachi M, Nagata S: Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-36.
18. Aoki K, Kurooka M, Chen JJ, Petryniak J, Nabel EG, Nabel GJ: Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001; 2:333-37.
19. Budd RC, Yeh WC, Tschopp J: cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006;6:196-204.
20. Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ, et al.: Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006;311:1160-64.
21. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug induced apoptosis in leukemia cells. Nat Med 1996;2:574-577.
22. Neuber K, Eidam B: Expression of fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie 2006;29:361-365.